This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Technische Universitat Dortmund. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Rajesh Gontla: Innovator in Cancer Therapy
Introduction
Rajesh Gontla is a notable inventor based in Dortmund, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development of kinase inhibitors. His work is aimed at improving the diagnosis and treatment of cancer, showcasing his commitment to advancing medical science.
Latest Patents
Rajesh Gontla holds a patent for "Kinase inhibitors and their use in cancer therapy." This invention relates to a 2,3-diphenyl-1,6-naphthyridine-5-one derivative, which is utilized in the diagnosis or treatment of cancer. The patent highlights the potential of this derivative in providing new therapeutic options for cancer patients.
Career Highlights
Gontla is affiliated with Technische Universität Dortmund, where he engages in cutting-edge research. His academic background and professional experience have positioned him as a key figure in the field of cancer research. His dedication to innovation is evident in his patent and ongoing research efforts.
Collaborations
Rajesh Gontla has collaborated with esteemed colleagues, including Jörn Weisner and Daniel Rauh. These partnerships enhance the scope of his research and contribute to the advancement of cancer therapies.
Conclusion
Rajesh Gontla's work in developing kinase inhibitors represents a significant advancement in cancer therapy. His contributions are vital to the ongoing fight against cancer, and his innovative spirit continues to inspire future research in this critical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile